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ABSTRACT
Purpose: To estimate the population-based incidence of acute idiopathic optic neuritis (ON) and
analyse its differential diagnosis in patients referred with symptoms suggestive of ON.
Methods: Patients with suspected ON referred to the Helsinki University Hospital, serving a
population of 1.5 million in Southern Finland, were reviewed between 1st May 2008 and 14th
April 2012. Brain and optic nerve magnetic resonance imaging (MRI) was performed within
24 hours in 83% of patients.
Results: Of 291 referred patients, 184 (63%; 95% confidence interval [CI], 57–69%) were diagnosed
with ON whereas 107 (37%) had another condition. The estimated crude incidence of ON in
Southern Finland was 3.0 (95% CI 2.8–3.3) per 100,000 (females, 4.6 and males, 1.4). Mean age was
34 years (range 15–61), 76% were female. Two (1%) were diagnosed with neuromyelitis optica. ON
as the first demyelinative episode was diagnosed in 108 (59%) patients, and MRI showed
demyelinating lesions (MRI+) in 82% (95% CI, 75–89) of them. MRI+ predicted the development
of multiple sclerosis (MS): 54% of MRI+ vs. 5% MRI− patients were diagnosed as MS during a mean
follow-up of 7.7 years. The most common differential diagnosis was non-arteritic anterior ischemic
optic neuropathy (12%). Six (2%) intracranial compressive lesions were found upon MRI scan.
Conclusions: More than a third of patients with symptoms suggestive of ON had another
condition. Demyelinative lesions on MRI indicated higher risk of developing MS. We recommend
the use of MRI to improve the differential diagnostic accuracy of ON and to identify patients with
high risk of MS.
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Introduction
Acute idiopathic optic neuritis (ON) is an inflammatory
optic neuropathy that leads to subacute vision loss. It is a
demyelinating disease that mostly affects young adults. The
most common symptom of ON is decreased visual acuity.
The diagnosis of ON is essentially clinical. No universal
diagnostic criteria are available1 and no specific treatment
is known for ON. According to the Optic Neuritis
Treatment Trial, intravenous high-dose corticosteroids
may hasten visual recovery, but they do not improve the
6-month and 1-year outcome of visual acuity as compared
to placebo.2,3
ON is the presenting symptom of relapsing multiple
sclerosis (MS) in about 20% of cases and eventually
occurs in about half of MS patients.4–6 MS typically
causes demyelination at multiple foci of the cerebrum,
brainstem, or spinal cord. It presents with a wide range
of signs and symptoms, including pareses of the limbs
or cranial nerves, ataxia, sensory disturbances as well as
autonomic nervous system (e.g. urinary incontinence)
and cognitive symptoms.7
Another demyelinating disease that can manifest with
ON is neuromyelitis optica (NMO, or Devic’s disease). ON
is not only a common initial symptomofNMObut also one
of its main diagnostic criteria. NMO is additionally char-
acterized by spinal symptoms from longitudinally extensive
myelitis. Aquaporin-4 (AQP4) antibodies are considered
an important adjunct for diagnosing NMO.8,9 In AQP4-
seropositive patients, more heterogeneous clinical symp-
toms are allowed in the newest diagnostic criteria.10 NMO
often leads to severely impairedmobility and reduced visual
acuity or even legal blindness.8,11 The incidence of NMO
among ON patients is low in Finland12,13 whereas the
incidence and prevalence of MS are relatively high.14–16
Here, we followed up 291 patients with acute or
subacute visual impairment suggestive of ON to iden-
tify differential diagnostic mimickers of ON, relation of
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ON with demyelinative diseases and the value of mag-
netic resonance imaging (MRI) in the diagnostic and
prognostic work-up.
Materials and methods
All patients referred to the Department of Ophthalmology,
Helsinki University Hospital, Finland, between 1st May
2008 and 14th April 2012 (a period of 47.5 months) with
symptoms suggestive of acute or subacute ONwere eligible
for inclusion in this study. A subsequent diagnosis of MS
was monitored during follow-up until end of 2017. Mean
follow-up time was 7.7 years. The hospital receives virtually
all patients with an acute ON living in its catchment area,
the Hospital District of Helsinki and Uusimaa in Southern
Finland. This region had amean population of 1.53million
during our study period (28% of the population of Finland,
5.4 million in 2011). Our series is thus essentially popula-
tion-based for the geographic catchment area and free of
administrative selection criteria. Of 300 eligible patients,6 9
were excluded because of clerical errors (miscoded diagno-
sis or personal identification error).
For the diagnosis of ON, we adhered to some of the
most common criteria: a combination of acute or suba-
cute loss of vision, possible relative afferent pupillary
defect, pain upon eye movements, and some degree of
acquired colour vision deficiency. Biomicroscopic exam-
ination of the fundus was performed in all patients and
indirect ophthalmoscopy in most of them. Visual fields,
visual evoked potentials (VEP), and optical coherence
tomography (OCT) were performed as needed to ensure
the diagnosis of ON.17
MRI of the brain and orbits was performed within
24 hours from the admission to hospital, either with
Siemens Avanto 1.5T (Siemens AG, Erlangen, Germany),
Philips Achieva 3T (Philips Healthcare, Eindhoven, The
Netherlands), or Siemens Verio 3T (from 2011). The MRI
included T2, T2 flair, diffusion-weighted, and T1 sequences
with gadolinium enhancement. MRI was not performed in
49 patients in the acute phase for various reasons: in 41
patients, MRI had been performed recently as a part of MS
patient follow-up, four patients were referred immediately
to a neurologist before MRI screening, and five patients
had other causes (e.g. claustrophobia). A spinal MRI was
obtained in all patients with spinal cord symptoms or
positive or borderline AQP4 index, which we tested in all
patients.12
Results
During the study period, 291 patients with a condition
suggestive of ON were referred; 184 (63%; 95% confidence
interval [CI], 57–69) were diagnosed with ON of which 39
(21%) had optic disc swelling suggesting that most ON
cases were retrobulbar. About 107 (37%) patients were
eventually diagnosed with another condition (Table 1).
The most common specific disease in the latter group
was non-arterial ischemic optic neuropathy (NAION). It
occurred in 12% of the patients and other conditions made
up the remainder, including 22 with ON-like symptoms
that resolved quickly (Figure 1).
Incidence of optic neuritis and its relation to
demyelinative diseases
The estimated crude incidence of ON in Southern Finland
was 3.0 (95% CI, 2.8–3.3) per 100,000 (females, 4.6 and
males, 1.4 per 100,000). The mean age was 34 years (range,
15–61 years) and 76% were female. The first ON was
observed in 123 (67%) patients. Two patients (1%) with
Table 1. Characteristics of six patients with an intracranial expansion.
Diagnosis
Age
(years) Sex Symptoms at onset Clinical findings Treatment
Meningioma dislocating
the left optic nerve
40 Female VA of the left eye reduced in two weeks VA 0.8/1.0
RAPD −/+, left optic disc
pale
Neurosurgery
Meningioma compressing the
right optic nerve
40 Female VA of the right eye reduced in one day VA CF/1.0
RAPD −/−
right optic disc pale
Neurosurgery
Meningioma with chiasmal
compression
65 Female VA slowly reduced in both eyes VA 0.3/0.6
RAPD −/−
both optic discs pale
Neurosurgery
Intracranial aneurysm
(both ophthalmic arteries)
49 Female VA of the right eye reduced in one week VA 0.1/1.0
RAPD ±
pain with eye movements
Neurosurgery
Intracranial aneurysm
(anterior communicating
artery)
52 Male Four days of pain with movements of the right
eye
VA 0.5/1.0
RAPD −/−
Refused surgery
Metastasis (lung cancer) 73 Female VA slowly reduced in both eyes VA 0.6/0.5. RAPD +/−
right optic disc swelling,
paresisabducens
Palliative
radiotherapy
CF = counting fingers, VA = visual acuity, RAPD = relative afferent pupillary defect.
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their first ON were diagnosed with NMO, and 56 patients
(30%) had a previous diagnosis of MS. ON as the first
demyelinative episode was diagnosed in 108 (59%)
patients, and 3 (2%) patients had a recurrent ON without
a diagnosis of MS.
Of the 108 patients with their first ON and without a
prior diagnosis of MS, 103 were MRI screened: 84 (82%)
had at least one demyelinative lesion on MRI (MRI+) and
19 (18%) did not have any lesions in MRI (MRI). Of these
patients, 26 (21%) had lesions in the optic nerve only, 44
(36%) had a lesion both in the optic nerve and in the brain,
and 14 (11%) in the brain only. Of the MRI+ patients with
their first ON, 45 (54%) were diagnosed with MS during
our follow-up (mean, 7.7 years) whereas only one (5%) of
MRI− patient was diagnosed with MS: positive predictive
value, 54%, negative predictive value, 94%. Three patients
with recurrent ONhad no previous diagnosis ofMS, two of
them were MRI+ and both were diagnosed with MS, while
the one MRI− case did not fulfil criteria of MS during
follow-up. Flow chart of the MRI findings and develop-
ment of demyelinative diseases is shown in Figure 2.
MRI findings of non-ON patients
Notably, 6 (2%) of the 291 patients with suspected ON
had intracranial compressive lesion on MRI. These
included three meningiomas, two intracranial aneur-
ysms, and one lung cancer metastasis (Table 1).
Discussion
Recent estimates on the incidence of acute idiopathic ON
are scarce. Most data are from the time period beforeMRI
was a common procedure, and even today in many cen-
tres the diagnosis of ON is often made without a brain
MRI. With modern diagnostic means (e.g. MRI, OCT,
NAION
12%
Optic nerve diseases 
(excluding NAION)
10%
Retinal diseases
11%
intracranial 
compressive lesions
6%
Other diagnoses
21%
No definite diagnoses
21%
Infectious / 
inflammatory diseases
19%
Figure 1. Differential diagnoses of patients with symptoms suggestive of optic neuritis at onset (n=107). Most common differential
diagnose was non-arteritic ischemic optic neuropathy (NAION, 12%). 21% patients had optic neuritis-like symptoms that resolved
quickly and no definite diagnosis was determined for them.
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VEP), it is easier to make the differential diagnosis and,
therefore, the incidence figures are becoming more reli-
able since some mimickers of ON can be differentiated
from ON.18–21 Our study found an incidence of 3.0 per
100,000, which is slightly higher than the earlier incidence
2.4 per 100,000 in Southern Finland from a period 1970 to
1978 when MRI and most of the other ancillary methods
were not utilized22. It is likely that the incidence of ONhas
increased slightly more than the figures directly indicate,
because of the probably lower number of false positive
cases in our present study. On the other hand, the devel-
opment of the health-care system in Finland may
nowadays find more often the ON patients then during
the previous study in the 1970s. Today, people also more
actively search medical help with even minor symptoms,
which may increase the incidence as well.
The incidence of ON varies a lot around the world
(Table 2). The high incidence of 5.4 per 100,000 in a quite
recent study from Spain23 suggested that the incidence of
ON is on the rise. The population of that study is quite
small (300,000) and the study area is limited to a small
part in Spain, Barcelona area, so these figures are not quite
comparable to other studies. Northern Europe and
Sardinia in Italy29 are known to be areas with high
291 patients suspected to have acute idiopathic optic neuritis (ON) at onset
184 ON patients
(44 males, 140 females)
107 patients with other
diagnosis than ON
123 First ON patients61 Recurrent ON patients
15 patients
with previous
diagnosis of MS3 non MS
patients
108 non MS patients 
84 MRI+19 MRI-
1 MS 2 NMO
16 ON
39 ON 45 MS
103 MRI screened
1 MRI- 2 MRI+
2 MS
1 ON
17 patients
diagnosed
with MS soon
after recurrent
ON
41 patients
with previous
diagnosis of MS 
Figure 2. Flow chart of patient recruitment.
Table 2. Summary of epidemiological surveys on acute idiopathic optic neuritis (ON) in chronological order.
Region Study period Population
Annual incidence per 100,000
Total Male Female
Finland (Uusimaa County) (present study) 2008–2012 1.5 million 3.0 1.4 4.6
Spain (Barcelona area)23 2008–2012 300,000 5.4 3.4 7.1
Singapore24 2002–2004 5.5 million 0.8 − −
Croatia
- Split-Dalmatia County
- Rijeka County25,26
1985–2001
1977–2001
− 1.6
2.2
1.1 2.2
Sweden (Stockholm area)27 1990–1995 1.6 million 1.5 0.6 2.3
USA (Olmsted County, Minnesota)28 1985–1991 − 5.1 2.6 7.5
Italy (Sardinia)29 1977–1986 − 2.4 − −
Finland
- Uusimaa County
- Vaasa County22
1970–1978 1.1 million
430,000
2.4
2.3
1.5
1.8
3.2
2.8
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incidence of MS. As ON is often related to MS, the lower
incidence of ON in these areas compared to the Barcelona
area is a bit surprising. The well-known observation that
MS is quite rare in Asia is well correlated with the low
incidence of ON in Singapore.24
Our study again confirmed that ON occurred more
often in females (ratio, 3:1). Bilateral ON (1.6%) and
NMO (1%) were rare. Almost a third (30%) of the patients
had a previous diagnosis of MS. Moreover, of the patients
who had ON as their first demyelinative episode, 82% had
demyelinating MRI lesions (MRI+). The presence of any
demyelinative lesions was a strong predictor of MS
because 54% of MRI+ patients vs. 5% of MRI− patients
developed MS during follow-up (positive and negative
predictive value, 54% and 94%, respectively). Since MRI
defines a subpopulation with a significant risk of MS, as
has been shown previously,30,31 an MRI scan should be
considered in the routine diagnostic work-up of ON to
facilitate early diagnosis and early treatment of MS. It is
becoming increasingly clear that early treatment is more
effective than delayed treatment in MS.32 The practice of
performing the MRI upfront, before any medical treat-
ment, is also supported by our finding of six intracranial
compressive lesions (2%) as mimickers of ON. In an-
other recent study from the USA, 4% of suspected ON
cases had optic sheath meningioma33 illustrating that
intracranial compressive lesions are not uncommon
mimickers of ON. There are also reports of optic nerve
lymphoma and optic nerve sheath melanoma cases as
serious compressive lesions mimicking ON.34,35
About one third (36%) of the patients were eventually
diagnosedwith a disease other thanON andMRI especially
aided in quick differentiation of ON from serious intracra-
nial compressive lesions. Except the cases with intracranial
expansion and one NAION patient who had optic disc
swelling, MRI findings were unremarkable in patients
who did not have ON. In our study, MRI was a very good
predictor of ON diagnosis because only 5% of patients in
the non-ON group had lesions in optic nerve or brain
typical for ON patients as compared to 78% of patients in
the group with first ON without previous diagnosis of MS.
Nevertheless, it is of note that 18% of cases with their first
ON did not have any lesions on MRI, stressing the impor-
tance of thorough clinical examination. Themost common
differential diagnosis was NAION, which often has similar
acute symptoms and signs as ON. NAION patients, how-
ever, are typically older, male, have more often cardiovas-
cular disease, and orbital MRI typically shows different
results between patients clinically diagnosed with either
ON or NAION.36 The latter patients also typically have a
small optic disk in both eyes (“disk-at-risk”).
There are limitations of our study that affect the general-
ization of the results. First, the study population was
focused on Southern Finland, and all patients were white
Caucasians. Thus, these results do not directly apply to
other ethnic groups with lower incidence of MS. Second,
not all patients necessarily seekmedical attention during an
acute ON which may cause bias in case ascertainment;
these include very mild cases and socially excluded citizens.
This study was approved by the Ethics Committee of
the Hospital District of Helsinki and Uusimaa (Dnro
83/13/03/01/2013).
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